

Date: 08/07/2025  
Our Ref: 10200  
Enquiries to loth.freedomofinformation@nhs.scot

Dear

## FREEDOM OF INFORMATION – MYELOMA TREATMENT

I write in response to your request for information in relation to myeloma treatment in NHS Lothian.

Question:

1. Is your health board currently treating myeloma patients?

Answer:

Yes.

Question:

2. Please list the hospitals in your board that are currently treating myeloma patients.

Answer:

Western General Hospital, and St John's Hospital, Livingston.

Question:

3. Please list how many myeloma patients are being treated a) by your health board b) broken down by hospital.

Answer:

The information you have requested is detailed in the table below.

Patients treated for myeloma, 17 March – 16 June 2025, NHS Lothian	
Hospital	Number of patients
Western General Hospital	194
St John's Hospital	48

Question:

4. Is your health board currently treating myeloma patients with elranatamab or teclistamab. Please break this down by hospital.

Answer:

Elranatamab is used in NHS Lothian at both the Western General Hospital and St John's Hospital. Teclistamab is not used in NHS Lothian.

## Question:

5. Please list how many people have been given a) elranatamab or b) teclistamab since approval by the Scottish Medicines Consortium in 2024 (SMC2669 and SMC2668) If possible, please break this down by hospital.

## Answer:

The numbers of patients treated with elranatamab are detailed in the table below. I have not released numbers of 5 or fewer in the table, as this information could lead to the identification of the individuals involved. Since we do not have their consent to release their personal data, the information is exempt under section 38 of the Freedom of Information (Scotland) Act 2002 as to provide it would breach the principles of the Data Protection Act 2018.

Myeloma treatment with elranatamab, 1 November 2024 to present, NHS Lothian	
Hospital	Number of patients
Western General Hospital	8
St John's Hospital	≤5

## Question:

6. Do you have a service level agreement or referral system in place with any other health boards to deliver a) elranatamab or b) teclistamab to patients. If the answer to question this is yes, which health boards do you have an agreement in place with.

## Answer:

NHS Lothian does not have a service level agreement in place for this treatment.

I hope the information provided helps with your request.

If you are unhappy with our response to your request, you do have the right to request us to review it. Your request should be made within 40 working days of receipt of this letter, and we will reply within 20 working days of receipt. If our decision is unchanged following a review and you remain dissatisfied with this, you then have the right to make a formal complaint to the Scottish Information Commissioner within 6 months of receipt of our review response. You can do this by using the Scottish Information Commissioner's Office online appeals service at <https://www.foi.scot/appeal>. If you remain dissatisfied with the Commissioner's response you then have the option to appeal to the Court of Session on a point of law.

If you require a review of our decision to be carried out, please write to the reviewer at the address at the top of this letter. The review will be undertaken by a Reviewer who was not involved in the original decision-making process.

FOI responses (subject to redaction of personal information) may appear on NHS Lothian's Freedom of Information website at: <https://org.nhsllothian.scot/FOI>

Yours sincerely

**ALISON MACDONALD**  
**Executive Director of Nursing Midwifery and AHPs**  
Cc: Chief Executive